VERTEX PHARMACEUTICALS INC / MA Form 8-K July 26, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2004

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319

(Commission File Number)

04-3039129

(I.R.S. Employer Identification No.)

130 Waverly Street
Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

(617) 444-6100

Registrant s telephone number, including area code:

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

Item 12. Disclosure of Results of Operations and Financial Condition.

On July 26, 2004, Vertex Pharmaceuticals Incorporated issued a press release to report the company s financial results for the quarter ended June 30, 2004. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information in this Form 8-K shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED (REGISTRANT)

DATE: July 26, 2004

By: /s/ IAN F. SMITH

Ian F. Smith

Senior Vice President and Chief Financial

Officer

EXHIBIT INDEX

The following exhibits are filed as part of this current report on Form 8-K:

Exhibit

No. Description

99.1 Press Release of Vertex Pharmaceuticals Incorporated dated July 26, 2004 entitled Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update.